NeuroOne Medical Technologies Corporation (NMTC)

1.77 -10.61% (-0.21)

Over 5Y: -92.8%

2026-08-28
10 20 30
2021 2022 2023 2024 2025 2026

Financials Quarterly

Q4 '21 — Revenue: 48.3K Q4 '21 — Operating Cash Flow: -2M Q4 '21 — Free Cash Flow: -2.1M Q4 '21 — Net Income: -2.6M Q1 '22 — Revenue: 33.7K Q1 '22 — Operating Cash Flow: -2.7M Q1 '22 — Free Cash Flow: -2.7M Q1 '22 — Net Income: -2.8M Q2 '22 — Revenue: 36.6K Q2 '22 — Operating Cash Flow: -3.2M Q2 '22 — Free Cash Flow: -3.3M Q2 '22 — Net Income: -3.1M Q3 '22 — Revenue: 32K Q3 '22 — Operating Cash Flow: -2.6M Q3 '22 — Free Cash Flow: -2.7M Q3 '22 — Net Income: -2.8M Q4 '22 — Revenue: 68.8K Q4 '22 — Operating Cash Flow: 1M Q4 '22 — Free Cash Flow: 951.6K Q4 '22 — Net Income: -1.4M Q1 '23 — Revenue: 114.6K Q1 '23 — Operating Cash Flow: -3.5M Q1 '23 — Free Cash Flow: -3.5M Q1 '23 — Net Income: -1.7M Q2 '23 — Revenue: 466.2K Q2 '23 — Operating Cash Flow: -3.6M Q2 '23 — Free Cash Flow: -3.7M Q2 '23 — Net Income: -3.5M Q3 '23 — Revenue: 629.9K Q3 '23 — Operating Cash Flow: -2.9M Q3 '23 — Free Cash Flow: -3.1M Q3 '23 — Net Income: -3.5M Q4 '23 — Revenue: 741.8K Q4 '23 — Operating Cash Flow: -2.9M Q4 '23 — Free Cash Flow: -3M Q4 '23 — Net Income: -3.1M Q1 '24 — Revenue: 977.6K Q1 '24 — Operating Cash Flow: -3.8M Q1 '24 — Free Cash Flow: -3.8M Q1 '24 — Net Income: -3.3M Q2 '24 — Revenue: 1.4M Q2 '24 — Operating Cash Flow: -2.2M Q2 '24 — Free Cash Flow: -2.2M Q2 '24 — Net Income: -2.9M Q3 '24 — Revenue: 825.8K Q3 '24 — Operating Cash Flow: -2.4M Q3 '24 — Free Cash Flow: -2.4M Q3 '24 — Net Income: -2.8M Q4 '24 — Revenue: 272.3K Q4 '24 — Operating Cash Flow: -2.7M Q4 '24 — Free Cash Flow: -2.7M Q4 '24 — Net Income: -3.4M Q1 '25 — Revenue: 3.3M Q1 '25 — Operating Cash Flow: 208K Q1 '25 — Free Cash Flow: 183.6K Q1 '25 — Net Income: 1.8M Q2 '25 — Revenue: 1.4M Q2 '25 — Operating Cash Flow: -56.1K Q2 '25 — Free Cash Flow: -59.3K Q2 '25 — Net Income: -2.3M Q3 '25 — Revenue: 1.7M Q3 '25 — Operating Cash Flow: -1.5M Q3 '25 — Free Cash Flow: -1.5M Q3 '25 — Net Income: -1.5M Q4 '25 — Revenue: 2.7M Q4 '25 — Operating Cash Flow: -1.5M Q4 '25 — Free Cash Flow: -1.5M Q4 '25 — Net Income: -1.6M Q1 '26 — Revenue: 2.9M Q1 '26 — Operating Cash Flow: -3.1M Q1 '26 — Free Cash Flow: -3.2M Q1 '26 — Net Income: -1.4M Q2 '26 — Revenue: 1.9M Q2 '26 — Operating Cash Flow: -1.3M Q2 '26 — Free Cash Flow: -1.4M Q2 '26 — Net Income: -2.4M Q3 '26 — Revenue: 2M Q3 '26 — Operating Cash Flow: -1.1M Q3 '26 — Free Cash Flow: -1.1M Q3 '26 — Net Income: -2M -3M -1.5M 0 1.5M 3M 4.5M
Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25 Q3 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

1.4
SBC / sales 14.9%
OE margin -90.6%
Oper. margin -83.4%
ROIC -861.4%
Accruals -6.4%
Gross margin 55.6%
EBITDA margin -80.9%
FCF margin -75.6%
OCF margin -74.5%
Profit margin -78.6%
ROA -120.4%
ROCE -190.6%
ROE -197.6%
OCF / EBIT —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

6.4
ND/EBITDA —
Cash runway 0.42 yr
Debt / Eq 0.0×
Debt payback 0.0 yr
Quick ratio 1.7×
F-score 5.6 pts
Cash / Debt —
Interest cover —
Payout —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

7.4
Sales CAGR 4Y +167.3%
Sales/sh Y/Y +42.8%
Sales Q/Q +16.3%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS CAGR 4Y —
EPS Y/Y —
EPS next Y —
Shares change —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.